anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Temporomandibular joint (TMJ) arthroscopy has been used successfully for intra-articular disorders. It was first introduced by Onishi at 1975, as a pioneering technique to treat painful joints and has been associated with a reduction in the number of open joints surgeries. This minimally invasive technique allows observation of the TMJ upper compartment tissues, and sometimes the lower compartment. Moreover, this intervention allows joint lysis and lavage (level 1 arthroscopy) and intra-articular surgical procedures (level 2-3 arthroscopy).

Recent studies updated that TMJ arthroscopy promotes a reduction in pain and inflammatory process and restoring the mandibular function with low morbidity. Moreover, TMJ arthroscopy seems to be also long-term effective for relieving TMJ symptoms. Until now, limited studies are available regarding the clinical evidence of bilateral TMJ arthroscopy for Dimitroulis 2-3. This prospective study investigated the efficacy of TMJ arthroscopy in patients with bilateral disorders, and also the need for a posterior surgery.
The standard of care arm will not use the mobile application Diabetes Doctor to communicate with their physician about their blood sugars. They will attend clinic visits and have evaluations initially, and at 3 and 6 months. They will also receive a HbAIc at each visit. They will do the same QOL survey at 3 months. At 6 months, they will be given the QOL survey.
Intervention to promote resilience and adjustment (RAI) is implemented in seven, 60-minute, virtual sessions; however individuals within this study arm will receive three additional 60-minute, virtual sessions three months after completing the seven initial sessions. The three booster sessions provide an opportunity for individuals to review course content, consolidate gains, and discuss challenges.
ETHNOPHARMACOLOGICAL RELEVANCE: Shenfu injection(SFI), as a famous classical Chinese patent medicine injection for the treatment of sepsis, has achieved good curative effects in clinical practice. However, its specific ingredients and molecular mechanisms is still unclear.
AIM OF THE STUDY: To analyze the effective ingredients and molecular mechanisms of SFI in the treatment of sepsis via network pharmacology technology and experimental validation.
MATERIALS AND METHODS: A total of 198 mice were used in this experiment. Septic mice model was performed by cecal ligation and puncture (CLP). First, Survival rates were calculted to screen the dosage and the treatment time window of SFI. Cardiac function was evaluated by echocardiography. The potential targets and pathways of SFI in the treatment of sepsis were predicted by network pharmacology. Myocardial tissue samples were harvest from different groups after CLP surgery. Hematoxylin-eosin (H&E) and TUNEL staining were used to examine the injury of heart. Western-blot analysis was performed to determine the protein expression of apoptosis. Meanwhile, the structural changes and mitochondrial membrane potential in the mitochondria of cardiomyocytes were also observed by transmission electron microscopy.
RESULTS: The Kaplan-Meier survival analysis showed that SFI significantly improved the 7-day survival rate as compared with that of CLP mice (P < 0.05). Echocardiography analysis found that LVEF and FS were significantly reduced in CLP mice compared with Sham mice, while SFI significantly increased LVEF (P < 001). Network pharmacology analysis indicated that the potential targets with higher degrees include IL2, BCL2, BAX, CASP7, BID, CASP8. Pathways with higher degrees include apoptosis, TNF signaling pathway, mitochondrial pathway apoptosis, PI3K-AKT signaling pathway. SFI treatment markedly attenuated the quantity of apoptotic cells as compared with the CLP group (P < 0.01). Western blot analysis indicated that CLP surgery decreased the expression of Bcl-2 (anti-apoptotic) but improved the protein expression of Bid, t-Bid, Cyc (pro-apoptotic) as compared with the Sham group (P < 0.01). While, SFI treatment markedly prevent the expression of Bid, t-Bid, Cyc and Caspase-9. The myocardial mitochondrial membrane potential of CLP group decreased after CLP surgery, while the mitochondrial membrane potential of SFI group increased significantly. Compared with the CLP group, in SFI group, the Z-line of the sarcomere was clear and distinguishable, and swollen mitochondria were significantly improved.
CONCLUSIONS: The present study demonstrated that SFI improved survival rate and cardiac function of septic mice mainly by suppressing inflammation and apoptosis.
It is intended to provide a polysaccharide containing chitosan, a process for producing the same and drugs and foods containing the same. Namely, a chitosan-containing polysaccharide which is obtained by heating a mushroom in an aqueous solution of a caustic alkali at a high concentration, subjecting the mixture to solid-liquid separation, dissolving the thus obtained solid matter in an aqueous solution of an organic acid, adding an alcohol or a caustic alkali thereto to form a precipitate, and then washing and drying the precipitate. This chitosan- containing polysaccharide is a compound wherein a glucosamine homopolymer is covalently bonded to glucan. The molar ratio of the constituting glucosamine to glucose ranges from 1 to 5:5 to 1. It has a molecular weight of about 150,000 and contains beta(1->4) bonds and beta (1->6) bonds but no beta(1->3) bond. It is free from proteins or reducing polysaccharides. This chitosan-containing polysaccharide is efficacious in preventing and treating life style- related diseases such as hypertension and diabetes.
INTRODUCTION: Desmoid tumor (DT) is a rare, locally aggressive, mesenchymal neoplasm that can arise at any site in the body. Medical therapies play a major role for DT's patients requiring treatment. A novel systemic approach has recently emerged with Nirogacestat, a γ-secretase inhibitor targeting the NOTCH signaling pathway.
AREAS COVERED: Nirogacestat is the first drug in its class to receive approval from the Food and Drug Administration (FDA) and is the first FDA-approved treatment specifically for DTs. We reviewed the data leading to its discovery, including its mechanism of action, pharmacological properties, clinical efficacy, and its positioning within the current treatment armamentarium for DTs.
EXPERT OPINION: High-quality evidence for systemic therapies in the management of DTs remains an unmet need. Nirogacestat now joins sorafenib as the only drugs with efficacy in DTs demonstrated by randomized phase 3 studies. Currently, there are no comparative trials of the available systemic therapies. Therefore, physicians should consider factors such as drug accessibility, cost, toxicity profile, comorbidities, and patient preferences when selecting treatment. Long-term efficacy and safety data will be essential for evaluating the duration of treatment response and monitoring late-onset side effects of Nirogacestat.
Participants allocated to mechanical lumbar traction received the McKenzie approach described above in combination with mechanical lumbar traction. The traction was applied using a 3D ActiveTrac table which is a motorized split table. Participants were placed in prone position and static traction was applied for 15 minutes at an intensity of 40% to 60% of the participant's body weight. At the end of traction intervention, participants continued with the McKenzie repeated back extension exercise intervention. The intervention was done 3 times per week for 6 weeks.
The safety and efficacy of JWCAR029 will be evaluated in a standard 3+3 dose escalation approach. 4 CAR T dosage will be tested in this study: 1×10\^7, 2.5×10\^7, 5×10\^7, 1×10\^8 CAR+ T cells.
PKC is a hyperkinetic movement disorder including dystonia, chorea, athetosis, or ballism, which are characteristically triggered by a sudden movement from rest. The prevalence of this disorder is estimated to be 1 in 150,000 population. Males are more commonly affected than females, and the age of onset is typically in childhood or adolescence. PKC is mainly a familial disorder with autosomal dominant inheritance and incomplete penetrance, but it can occur sporadically. The PRRT2 (proline-rich transmembrane protein 2) gene is believed to be the major causative gene.

The prognosis of PKC is usually favorable. The severity and frequency of the attacks are reduced by anticonvulsant medication such as carbamazepine, and the number of the attacks decreases at the age of 20-30 years. However, there has been little study of long-term prognosis of PKC, and no study has been conducted in Korean population.
Standard of care treatment and the experimental combination product. The PXL Platinum 330 Illumination System is a portable electronic medical device. The device's light emitting diode (LED) is used to deliver a metered dose of UV-A light to a targeted treatment area for illuminating the cornea during corneal collagen CXL. The riboflavin solution is an isotonic (0.9%) sodium chloride solution containing 0.25% riboflavin, 1% hydroxypropylmethylcellulose, and 0.007% benzalkonium chloride, adjusted to a pH of 7.0, and packaged in 2 mL sterile syringes for topical ophthalmic use.
Acute respiratory infections are a major cause of morbidity and mortality in children worldwide. Dietary and nutritional interventions, including minerals and vitamin supplementation, have been explored as potential treatments for these infections. However, the evidence on their efficacy is limited and inconclusive. This systematic review and meta-analysis aim to provide a comprehensive summary of the available evidence on the effectiveness of dietary and nutritional interventions for treating acute respiratory tract infections in children. A systematic review was conducted according to the PRISMA 2020 guidelines in April 2022 and updated in April 2023. Clinical trials focusing on dietary or nutritional interventions, including supplementations, in children with acute respiratory tract infections were included. The selection of interventions and outcomes was based on biological plausibility. Data were extracted using a standardized form, and the risk of bias was assessed using the Cochrane Risk of Bias Tool. Meta-analysis was performed using random-effect models. A total of 50 studies were included in the review. Four trials were conducted in low, 32 in lower-middle, 12 in upper-middle, and only two in high-income countries. The studies evaluated various dietary interventions, including zinc, vitamin A, vitamin E, vitamin D, and probiotics. The results of individual studies on the efficacy of these interventions were mixed, with some showing positive effects on clinical outcomes such as duration of symptoms, while others showed no significant impact. Meta-analysis was conducted for zinc supplementation in children with pneumonia, and the pooled results suggested a potential limited benefit in terms of reduced hospital length of stay but not time to recovery. Meta-analyses on vitamin D did not show any effect in children with pneumonia. This systematic review fills a critical gap in the literature by synthesizing the available evidence on the efficacy and safety of nutritional or dietary interventions for acute respiratory tract infections in children. The findings indicate no dietary or nutritional intervention can currently be recommended for the routine treatment of respiratory tract infections in children based on single supplement studies. The metanalysis suggests that zinc supplementation might have a beneficial effect on length of hospitalization in children with pneumonia. New studies are needed to establish more conclusive evidence for pediatric acute respiratory diseases especially for children living in a context of high-income countries.
The invention relates to a stevioside derivative prepared by stervioside biotransformation and a preparation method and an application thereof, and belongs to the field of food chemistry. According to the method, stervioside, which is used as a substrate, undergoes enzyme catalysis by the utilization of UDP-glucosyltransferase in the presence of a glucosyl donor under conditions of proper temperature, pH, salinity, substrate concentration and the like, so as to obtain a stevioside derivative NY101 with a brand-new structure. The method for preparing the stevioside derivative NY101 by stervioside biotransformation is simple to operate, is low-cost, and has high transformation efficiency. Transformation efficiency can be greater than 90%. Purification is easy, purity is high, and purity can be greater than 95%. The stevioside derivative NY101 can be used in the food and beverage industry and has huge potential application value.
PURPOSE:To provide the subject allergen useful for mite allergic disease- treating.preventing agents, etc., as an allergen for desensitized therapies by extracting mite excreta in mite culture products with a saturated salt aqueous solution, etc., and subsequently fractionating the produced extract solution by means of a gel filtration, etc. CONSTITUTION:Dermatophagoides farinae is reared in a mite density of 20000-30000 mites/g of a medium in a feed for rats, mouses or hamsters in an atmosphere comprising a temperature of 26+ or -2 deg.C and a humidity of 75%, and subsequently mixed with a saturated salt aqueous solution and/or a buffer solution having an approximately medium ion strength under stirring to extract the excreta in the feed. The extraction product is centrifuged, and the supernatant is collected. The mites floated on the supernatant are filtered off. The left extract solution is dialyzed with city water, subjected to an ultrafiltration using an ultrafiltration membrane having a fractionation mol.wt. of 10000 and further subjected to a gel filtration to provide the purified mite allergen which comprises a glucoprotein containing saccharides in an amount of approximately 13%, has a mol.wt. of about 13000 (by a gel filtration method), has an allergen activity and is useful as mite allergic disease-preventing.treating medicines, mite allergic disease-diagnosing medicines, etc.
PROBLEM TO BE SOLVED: To obtain a preparation for external use for skin, comprising an extract of a specific myrsinaceous plant or 1,4-benzoquinones contained in the extract as an active ingredient and having preventing effects on aging, antiinflammatory and beautifying and whitening effects together. SOLUTION: This preparation for external use comprises an extract of Ardisia japonica Blume, Ardisia quinquegona Blume and Ardisia sieboldi Miq. or 1,4-benzoquinones contained in the extract as an active ingredient. The blending concentration of the extract in the preparation for external use is about 0.1-1μM expressed in terms of the 1,4-benzoquinones and about 0.001-10wt.% in a state of a crude extract of the plant. The active ingredient has good scavenging actions on active oxygen species and further antiinflammatory actions based on inhibiting actions on 5-lipoxygenases and beautifying and whitening actions based on inhibiting actions, etc., on tyrosinases. The preparation is effective in reducing and preventing aging diseases of the skin mainly caused by oxidative stress, dermatitis, pigmentation such as dermal stains, ephelides or nevus Ota, blackening, etc., due to sunburn.
PURPOSE:To obtain the subject new substance, capable of inhibiting the activity against a prolyl endopeptidase and useful as an antiamnesic agent, a therapeutic agent, etc., for AIDS by culturing a microorganism(belonging to the genus Streptomyces and having the ability to produce an isotetracenone-based substance. CONSTITUTION:A microorganism, belonging to the genus Streptomyces and having the ability to produce an isotetracenone-based substance SNA-8073- B[Streptomyces sp. SNA-8073 (FERM P-13007), etc.] is inoculated into a culture medium and cultured at 27 deg.C for 9 days. The resultant culture solution is then centrifuged to remove the microbial cells. The obtained supernatant is collected and extracted with ethyl acetate and the prepared extract is freeze-dried to provide an oily substance, which is subsequently purified by high-performance liquid chromatography to afford the objective compound, expressed by the formula (Me is methyl) and having a specific rotatory power [alpha]<24>D=-137 deg. (c = 0.1, CHCl3) and a retention time of 10.4min in high-performance liquid chromatography [column; ODS-1251-N, solvent; methanol: water = 60:40, flow velocity; 0.8ml/min, detection; at 220nm].
Depression is a prevalent mental illness, affecting a significant portion of the global population. Recent research has highlighted the crucial role of the gut microbiota in both metabolic and central nervous health. By reviewing literature from various databases, including Pubmed, Science Direct, Web of Science, and Scopus, spanning the years 2005-2023, a comprehensive search was conducted using keywords such as "Depression" and "Gut Microbiota". The gut microbiota acts as a "second brain" in humans and can communicate bidirectionally with the brain through the Brain-gut-microbiota axis pathway. This communication involves the immune and nervous systems. However, there are challenges in detecting and treating depression effectively. To address these limitations, researchers have been exploring the relationship between gut microbiota and depression. Studies have shown that gut microbial metabolites, such as lipopolysaccharides and short-chain fatty acids, can induce pro-inflammatory cytokines that contribute to neuroinflammation and increase the risk of depression. The kynurenine pathway, triggered by gut microbial metabolites, has also been associated with neuroinflammation. Thus, investigating these microbial metabolites can provide insights into depression treatment. This review focuses on analyzing the connection between gut microbial metabolites, inflammation, and depression. It explores novel mechanisms contributing to depression, specifically focusing on the mediation of inflammation through the release of pro-inflammatory cytokines. The objective is to provide valuable insights into the mechanisms underlying depression and to propose potential treatments.
A fetal developmental stage is precisely determined. Then, fetal tissues are extracted for in vitro cultivation. Intact aborted fetal testicular tissues are cultured in a medium containing 1 IU/mL luteinizing hormone, which is the injectable solution powder. Luteinizing hormone is administered starting on the first day and then every other day, for a total of 7 times over the 14-day in vitro culture period.
Sorafenib 400 mg was administered orally at a dose of 400 mg (2 x 200 mg tablets) twice daily; 2 dose reductions to predefined levels of 400 mg once daily (OD) and 400 mg every other day were permitted for adverse events related to study treatment. Follow-up / Open Label phase: Subjects on sorafenib who continued the study, continued on the same dose of sorafenib as during the double-blind study.
PURPOSE:To provide an agent containing a 24-oxovitamin D3 compound as an active component, having low bonding capability to receptor protein and high differentiation-inducing property, and useful as an anti-tumor agent. CONSTITUTION:The objective anti-tumor agent contains the 24-oxovitamin D3 compound of formula (R<1> and R<2> are H or OH) as an active component. It has been clarified in recent years that a receptor having specificity to 1alpha,25-dihydroxyvitamin D3 is present in various subcultured tumor cells. The 1alpha,25-dihydroxyvitamin D3 suppresses the proliferation of the cancerous medullar cell, and remarkably promotes the differentiation. However, the activated vitamin D3 has strong calcium-motalizing activity as well as the differentiation-inducing capability, and has poor selectivity of the action. The activated vitamin D3 of formula has low bonding capability to receptor protein, and high differentiation-inducing capability excellent in the selectivity of the action.
The patients involved in the study will be randomly divided into two groups. One group will be provided with a set of headphones that completely cover the ears and will be played their selected music from a predetermined album for 20 minutes before the procedure. The music will continue to be played through the headphones during the procedure.
Four noncommunicable diseases (NCDs): cardiovascular diseases, cancers, chronic respiratory diseases, and diabetes, account for 71% of global deaths. However, little is known about the NCDs risk profile of sexual and gender minorities (SGMs). This study aimed to determine the prevalence of NCDs risk factors among the SGMs of Kathmandu valley, Nepal. A cross-sectional study was conducted among SGMs in the Kathmandu valley, Nepal. We recruited 140 participants using the snowball sampling method. A face-to-face interview was done using a structured questionnaire adapted from World Health Organization Step Wise Approach to Surveillance (STEPS instruments V2.2 2019) along with blood pressure and anthropometric measurements. Data were analyzed using Statistical Package for Social Science (SPSS.v20). More than two-thirds of the participants, 96 (68.6%), had co-occurrence of NCDs risk factors. The prevalence of insufficient fruits and vegetables consumption, current smoking, harmful alcohol consumption, overweight/obesity, and hypertension were 95.7%, 40.0%, 32.9%, 28.5%, and 28.6%, respectively. There was a significant association between hypertension, harmful alcohol consumption, and overweight/obesity with the participants' age, employment status, and marital status, respectively. Study findings indicated a higher prevalence of NCDs risk factors among SGMs. National-level NCDs surveillance, policy planning, prevention, and targeted health interventions should prioritize the SGMs.
BACKGROUND: Left ventricular free wall rupture (LVFWR) is a rare and fatal complication after acute myocardial infarction. Early recognition and aggressive treatment are recommended.
METHODS: Between August 1999 and February 2023, 11 patients aged between 64 and 79 years developed LVFWR after acute myocardial infarction (mean interval, 3.5 days). Three patients had active bleeding (blowout-type LVFWR), and the other 8 patients experienced the oozing or sealed state. Eight patients were treated using a sutureless technique with Teflon felt and glue, 2 patients were treated using the primary suture closure technique, and 1 was treated using both the primary suture and the sutureless technique with Teflon felt and glue.
RESULTS: One patient died in the operating room as a result of bleeding. Cardiovascular stability and hemostasis were achieved in the other 10 patients. There were 3 early deaths (all 3 cases as a result of area bleeding; 1 was treated with primary suture, 2 with sutureless glue). Three patients received percutaneous coronary intervention before discharge. All 8 remaining patients survived and were discharged. Three patients were lost to follow-up. The follow-up period ranged from 2 to 97 months, with 4 patients exhibiting New York Heart Association class I symptoms and 1 exhibiting New York Heart Association class II symptoms.
CONCLUSION: Optimal surgical treatment for postinfarction LVFWR remains controversial. The sutureless technique may be a promising strategy for treating postinfarction LVFWR.
Signs and symptoms of local skin irritation (such as erythema, scaling, dryness, stinging/burning) may be experienced with use of DIFFERIN Lotion. These are most likely to occur during the first 2 weeks of treatment, are mostly mild to moderate in severity, and usually lessen with continued use of DIFFERIN Lotion. Depending upon the severity of these side effects, patients should be instructed to use a moisturizer, reduce the frequency of the application of DIFFERIN Lotion 0.1%, or discontinue use.

DIFFERIN Lotion should not be applied to cuts, abrasions, eczematous or sunburned skin. As with other retinoids, use of “waxing” as a depilatory method should be avoided on skin treated with DIFFERIN Lotion.

Avoid concomitant use of other potentially irritating topical products (abrasive soaps and cleansers, soaps and cosmetics that have strong skin-drying effect and products with high concentrations of alcohol, astringents, spices, or limes).